Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR-7787 injection in combination with other antitumor drugs in malignant solid tumors
CTR20254693Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-7787 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
SHR-7787
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254693.